» Articles » PMID: 17985402

Natural History of Ischemic Digital Ulcers in Systemic Sclerosis: Single-center Retrospective Longitudinal Study

Overview
Journal J Rheumatol
Specialty Rheumatology
Date 2007 Nov 7
PMID 17985402
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To describe the natural history of ischemic digital ulcers (DU) in systemic sclerosis (SSc).

Methods: This single-center, retrospective, longitudinal study identified patients by demographic data, SSc history and type, Rodnan score, tobacco use, presence of autoantibodies, ongoing treatment, and DU history.

Results: One hundred three patients were enrolled, 46 with DU history and 57 without; 2 with DU were excluded. The mean duration of followup from the first non-Raynaud SSc symptoms was 12.3 +/- 6.3 years in patients with DU history and 12.1 +/- 7.0 years in patients without. In 43% of cases, first DU occurred within 1 year following first non-Raynaud SSc symptoms, and within 5 years in 73% of cases. In a multivariate analysis, younger patients at occurrence of first non-Raynaud SSc symptoms (HR = 0.77 per each 5 years older, 95% CI 0.66-0.90) with higher Rodnan scores (HR = 1.21 per 5 points, 95% CI 1.05-1.47) experienced earlier DU occurrences, which were delayed by vasodilator therapy (HR = 0.17, 95% CI 0.09-0.32). Patients with shorter durations between first and second DU episodes, particularly with a second episode within 2 years of the first, experienced a higher yearly incidence of DU episodes (0.85 +/- 0.57 and 0.48 +/- 0.26, respectively, if less or more than 2 yrs; p = 0.04). Throughout the duration of followup, the incidence of finger amputation was 1.2% per patient-year in patients with DU history.

Conclusion: Patients who are young at first sign of SSc, with high Rodnan scores and without vasodilator therapy, are at high risk of developing DU. Development of DU typically occurred within 5 years of the first non-Raynaud clinical symptom of SSc in the majority of patients.

Citing Articles

Impact of autoantibody status on stratifying the risk of organ involvement and mortality in SSc: experience from a multicentre French cohort of 1605 patients.

Didier K, Sobanski V, Robbins A, Truchetet M, Barnetche T, Contin-Bordes C RMD Open. 2024; 10(4).

PMID: 39572073 PMC: 11580297. DOI: 10.1136/rmdopen-2024-004580.


Efficacy and safety of digital nerve block for pain management during sharp debridement of digital ulcers in systemic sclerosis: A prospective observational study.

Bixio R, Mastropaolo F, Nava F, Veliaj O, Fracassi E, Viapiana O J Scleroderma Relat Disord. 2024; :23971983241285206.

PMID: 39544895 PMC: 11559528. DOI: 10.1177/23971983241285206.


Development of a measuring app for systemic sclerosis-related digital ulceration (SALVE: Scleroderma App for Lesion VErification).

Davison A, Krishan A, New R, Murray A, Dinsdale G, Manning J Rheumatology (Oxford). 2024; 63(12):3297-3305.

PMID: 39029921 PMC: 11637552. DOI: 10.1093/rheumatology/keae371.


[Systemic sclerosis].

Faber A, Krieg T, Hunzelmann N Dermatologie (Heidelb). 2024; 75(3):181-196.

PMID: 38366245 DOI: 10.1007/s00105-024-05298-8.


Preliminary nomogram model for predicting irreversible organ damage of patients with systemic sclerosis.

Huo X, Huang X, Yang Y, Wei C, Meng D, Huang R Rheumatology (Oxford). 2024; 64(2):658-666.

PMID: 38317497 PMC: 11781586. DOI: 10.1093/rheumatology/keae083.